Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
18.74
-0.15 (-0.79%)
Nov 13, 2026, 4:00 PM EST - Market closed
Denali Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -314.42 | -512.54 | -422.77 | -145.22 | -325.99 | -290.58 |
Depreciation & Amortization | 16.52 | 14.81 | 8.99 | 8.83 | 10.38 | 8.59 |
Loss (Gain) From Sale of Assets | -194 | - | -14.54 | - | - | - |
Asset Writedown & Restructuring Costs | - | - | - | 7.9 | - | - |
Loss (Gain) From Sale of Investments | -5.36 | -10.25 | -35.12 | -43.95 | -1.64 | 8.75 |
Stock-Based Compensation | 92.81 | 99.63 | 102.88 | 108.1 | 99.85 | 85.25 |
Other Operating Activities | 5.78 | -4.4 | -4.07 | -3.72 | -3.29 | -2.98 |
Change in Accounts Payable | 9.6 | -7.52 | 1.44 | 2.43 | 2.27 | 3.71 |
Change in Unearned Revenue | - | - | - | -290.53 | -34.46 | -15.66 |
Change in Other Net Operating Assets | -9.95 | 7.67 | 15.5 | -1.83 | 8.16 | -8.46 |
Operating Cash Flow | -444.19 | -412.6 | -347.69 | -357.99 | -244.72 | -211.39 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -5.81 | -9.5 | -15.91 | -12.94 | -17.83 | -8.5 |
Investment in Securities | -124.85 | 264.78 | -72.84 | 262.25 | -123.55 | -13.13 |
Investing Cash Flow | 27.34 | 255.28 | -88.76 | 249.31 | -141.39 | -21.63 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Repaid | - | -8.17 | -32.34 | - | - | - |
Net Debt Issued (Repaid) | -0.08 | -8.17 | -32.34 | - | - | - |
Issuance of Common Stock | 957.2 | 925.71 | 517.12 | 17.82 | 311.73 | 19.35 |
Other Financing Activities | -528.37 | -728.32 | -0.48 | - | -1.06 | - |
Financing Cash Flow | 428.75 | 189.22 | 484.3 | 17.82 | 310.67 | 19.35 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash Flow | 11.91 | 31.9 | 47.85 | -90.86 | -75.43 | -213.67 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -449.99 | -422.1 | -363.61 | -370.93 | -262.55 | -219.89 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -2104.54% | - | - | -112.22% | -242.06% | -451.88% |
Free Cash Flow Per Share | -2.44 | -2.44 | -2.21 | -2.70 | -2.09 | -1.81 |
Levered Free Cash Flow | -301.32 | -244.19 | -200.74 | -298.35 | -141.03 | 200.41 |
Unlevered Free Cash Flow | -301.32 | -244.19 | -200.74 | -298.35 | -141.03 | 200.41 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 0.72 | 0.72 | 0.3 | - | - | - |
Cash Income Tax Paid | 0.05 | 0.05 | - | 0 | 0.05 | 0.21 |
Change in Working Capital | -45.51 | 0.15 | 16.94 | -289.93 | -24.03 | -20.41 |